Arvee Laborat. (ARVEE)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Very low debt/equity of 0.03 gives strong balance-sheet safety
• Promoter holding at 73.5% aligns management with minority shareholders
• Piotroski F-Score of 7/9 indicates improving fundamentals
• Latest quarter shows a sharp margin improvement: ₹2 Cr profit on ₹10 Cr sales
• Sales growth of 9.76% is positive, albeit modest

Concerns

• P/E of 82.12 and P/B of 6.13 leave no margin of safety
• ROCE of 10% is modest for a company valued at 6 times book
• Profit growth of 1,000% is off a very low base and likely unsustainable
• No dividend yield, so shareholders rely entirely on price appreciation

AI Analysis

At ₹171.95, Arvee Laboratories is not a stock I would call a bargain. The market cap is ₹171 Cr, but trailing earnings support a P/E of 82.12. Book value is ₹28.06, so I am paying 6.13 times book for a specialty chemical company whose ROCE is only 10%. That is not the kind of return on capital that excites me. The 1,000% profit growth looks spectacular, but it is off a tiny base; the latest quarter net profit of ₹2 Cr on sales of ₹10 Cr is good, but one quarter does not make a durable franchise. Sales growth is just 9.76%, so the profit jump is mostly margin recovery, not compounding demand. On the positive side, debt/equity is 0.03, so the balance sheet is very safe. Promoter holding at 73.5% aligns ownership with public shareholders. The Piotroski F-score of 7/9 suggests improving fundamentals. But I do not pay 82 times earnings for a small specialty chemicals player without a proven moat. If the company can sustain a 20% net margin, then annualised profit would be around ₹8 Cr, putting the P/E nearer 21, which is more reasonable. But that is a big 'if'. The PEG ratio of 0.16 is misleading because it is based on a 1,000% profit spike, not normalised growth. I would watch whether sales growth accelerates and whether profit margins hold above 15-20%. Right now, this is an interesting small-cap turnaround candidate, not a Graham-style margin of safety. I would wait for a lower price or a longer track record of profitable growth.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer